<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04878913</url>
  </required_header>
  <id_info>
    <org_study_id>VP-C21-007</org_study_id>
    <nct_id>NCT04878913</nct_id>
  </id_info>
  <brief_title>Retrospective Evaluation of Lung Pathology in Subjects With COVID-19</brief_title>
  <acronym>ATTRACT-2</acronym>
  <official_title>Non-interventional, Retrospective, Multicenter, Follow-up Study Evaluating the Effect of C21 on Lung Pathology in Subjects Previously Hospitalized With COVID-19 and Enrolled in the VP-C21-006 Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vicore Pharma AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vicore Pharma AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-interventional, retrospective, multi-center, follow-up study evaluating the effect of C21&#xD;
      on lung pathology in subjects previously hospitalised with COVID-19 and enrolled in the&#xD;
      VP-C21-006 trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will collect available HRCT scans obtained prior to, during treatment with C21 or&#xD;
      placebo and up to 24 weeks after trial completion.&#xD;
&#xD;
      HRCT scans will be assessed for ground glass opacity, reticulation, band opacity, fibrosis&#xD;
      and consolidation by a central, blinded HRCT reader.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Actual">August 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Averaged total lung score for both lungs percent measured by per lung percent scores</measure>
    <time_frame>Up to 24 weeks after completion of VP-C21-006</time_frame>
    <description>Based on ground glass opacity, reticulation, band opacity, fibrosis and consolidation, on HRCT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in percent lung involvement measured totally (averaged total lung score for both lungs percent) and by each of ground glass opacity, reticulation, band opacity, fibrosis and consolidation on follow-up HRCT</measure>
    <time_frame>Up to 24 weeks after completion of VP-C21-006</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">39</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>C21</arm_group_label>
    <description>Subject treated with C21 in the VP-C21-006 trial</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <description>Subject treated with placebo in the VP-C21-006 trial</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with a previous COVID-19 infection enrolled in the VP-C21-006 trial.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Previously included in the VP-C21-006 trial and received at least one dose of&#xD;
             investigational medicinal product (IMP)&#xD;
&#xD;
          -  Available record of at least one HRCT performed within 24 weeks after completion of&#xD;
             VP-C21-006.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participation in another interventional trial during the historical period covered by&#xD;
             this study that could interfere with the study objectives or evaluation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Rohit Batta, MD</last_name>
    <role>Study Director</role>
    <affiliation>Vicore Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Medicine, Civil Hospital and B J Medical College</name>
      <address>
        <city>Ahmadabad</city>
        <state>Gujarat</state>
        <zip>380016</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Floor Clinical Research Department Rhythm Heart Institute</name>
      <address>
        <city>Vadodara</city>
        <state>Gujarat</state>
        <zip>290022</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Medicine, Government Medical College and Hospital</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>440003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Medicine, Noble Hospitals Pvt. Ltd</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <link>
    <url>https://www.medrxiv.org/content/10.1101/2021.01.26.21250511v1</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Tornling G, et al. The angiotensin type 2 receptor agonist C21 restores respiratory function in COVID19 - a double-blind, randomized, placebo-controlled Phase 2 trial, medRxiv, 2021</citation>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 4, 2021</study_first_submitted>
  <study_first_submitted_qc>May 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2021</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

